This article was originally published on 1 October 2014 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.
An outbreak of unprecedented scale
The Ebola virus disease (EVD) outbreak that began in Guinea in March 2014 has become the largest in recorded history, with 6,553 probable and suspected cases and 3,083 deaths across Guinea, Liberia, Sierra Leone, Nigeria, Congo and Senegal as of early October. By comparison, the first significant outbreak in Zaire in 1976 comprised 318 cases. Experts estimated that between 550,000 and 1.4 million people could be infected across West Africa by January 2015, making headlines globally.
Probable and suspected Ebola cases in the 2014 West African outbreak - the largest in recorded history
ZMapp and the therapy gap
No vaccine or antiviral had been proven effective against Ebola prior to this outbreak. ZMapp™, a cocktail of three monoclonal antibodies manufactured in Nicotiana plants by San Diego-based Mapp Biopharmaceuticals, was granted emergency use authorisation by the US FDA despite never having been shown to be safe and effective in humans. Supplies were quickly exhausted. In early September, US BARDA announced an 18-month contract worth $42.3 million with Mapp to advance ZMapp™.
Phase I vaccines fast-tracked
The NIH's National Institute of Allergy and Infectious Diseases (NIAID) announced they were expediting an Ebola vaccine candidate (ChAd3) developed in collaboration with GlaxoSmithKline Biologicals, entering Phase I clinical trials as part of a wider international consortium. The NIH was also supporting a Crucell (Johnson & Johnson) candidate. Other early-stage programmes included BioCryst, NewLink (with the Public Health Agency of Canada's VSV-ZEBOV), Inovio, Profectus and Tekmira.
"Unless we fund significantly every possible rare pathogen associated with outbreak potential and high mortality, we will always be caught short by our inherent nature to prioritise precious resources."
Perspective
The apparent lack of past urgency around Ebola therapies is controversial. But the structural reality is that without a clear commercial return or sustained government procurement commitment, it is rational for private industry to allocate R&D resources elsewhere. The Ebola crisis has ignited political will and emergency funding. The challenge is to maintain that momentum beyond the immediate outbreak so that the infrastructure for rapid response to future rare pathogen emergencies is not again allowed to wither.